Thaman Rajesh, Esteban Maite Tome, Barnes Sophie, Gimeno Juan R, Mist Bryan, Murphy Ross, Collinson Paul O, McKenna William J, Elliott Perry M
The Heart Hospital, University College London, London, United Kingdom.
Am J Cardiol. 2006 Aug 15;98(4):515-9. doi: 10.1016/j.amjcard.2006.02.057. Epub 2006 Jun 27.
Most patients with hypertrophic cardiomyopathy (HC) have reduced maximal oxygen consumption (VO2max) during exercise. The degree of impairment is poorly predicted by the magnitude of hypertrophy, left ventricular (LV) outflow tract obstruction, and other conventional markers of disease severity. The aim of this study was to determine the usefulness of N-terminal-pro-B-type natriuretic peptide (NT-pro-BNP) as a marker of exercise performance in HC. Plasma NT-pro-BNP was measured in 171 consecutive patients (mean age 46 +/- 18 years) who underwent echocardiography and cardiopulmonary exercise testing. The mean log NT-pro-BNP was 2.79 +/- 0.5; log NT-pro-BNP levels were higher in women patients (p = 0.001) and patients with chest pain (p = 0.010), in New York Heart Association class > or = II (p = 0.009), with atrial fibrillation (p < 0.001), with systolic impairment (p = 0.025), and with LV outflow tract obstructions (p < 0.0001). NT-pro-BNP levels were also correlated with maximal wall thickness (r = 0.335, p < 0.0001), left atrial size (r = 0.206, p = 0.007), and the mitral Doppler E/A ratio (r = 0.197, p = 0.012). The mean percent VO2max achieved was 73.8 +/- 22.6%; percent VO2max was smaller in patients with systolic impairment (p = 0.044) and LV outflow tract obstructions (p = 0.025). There were inverse correlations between percent VO2max and NT-pro-BNP (r = -0.352, p = 0.001), LV end-systolic cavity size (r = -0.182, p = 0.031), and left atrial size (r = -0.251, p = 0.003). On multivariate analysis, only NT-pro-BNP was correlated with percent VO2max. A NT-pro-BNP level of 316 ng/L had 78% sensitivity and 44% specificity (area under the curve 0.616) for predicting percent VO2max < 80%. In conclusion, NT-pro-BNP levels correlate with peak oxygen consumption in HC and are more predictive of functional impairment than other conventional markers of disease severity.
大多数肥厚型心肌病(HC)患者运动时最大摄氧量(VO2max)降低。肥厚程度、左心室(LV)流出道梗阻及其他传统疾病严重程度标志物对功能损害程度的预测效果不佳。本研究旨在确定N末端B型利钠肽原(NT-pro-BNP)作为HC患者运动表现标志物的效用。对171例连续接受超声心动图和心肺运动试验的患者(平均年龄46±18岁)测定血浆NT-pro-BNP。平均log NT-pro-BNP为2.79±0.5;女性患者(p = 0.001)、胸痛患者(p = 0.010)、纽约心脏协会心功能分级≥II级(p = 0.009)、心房颤动患者(p < 0.001)、收缩功能损害患者(p = 0.025)及LV流出道梗阻患者(p < 0.0001)的log NT-pro-BNP水平较高。NT-pro-BNP水平还与最大壁厚(r = 0.335,p < 0.0001)、左心房大小(r = 0.206,p = 0.007)及二尖瓣多普勒E/A比值(r = 0.197,p = 0.012)相关。达到的平均VO2max百分比为73.8±22.6%;收缩功能损害患者(p = 0.044)和LV流出道梗阻患者(p = 0.025)的VO2max百分比更低。VO2max百分比与NT-pro-BNP(r = -0.352,p = 0.001)、LV收缩末期腔径(r = -0.182,p = 0.031)及左心房大小(r = -0.251,p = 0.003)呈负相关。多因素分析显示,仅NT-pro-BNP与VO2max百分比相关。NT-pro-BNP水平为316 ng/L时,预测VO2max百分比<80%的敏感度为78%,特异度为44%(曲线下面积0.616)。总之,HC患者的NT-pro-BNP水平与峰值耗氧量相关,且比其他传统疾病严重程度标志物更能预测功能损害。